Teva Pharmaceutical Industries Limited (TEVA) EPS Estimated At $0.53

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Logo

Analysts expect Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report $0.53 EPS on February, 14.They anticipate $0.38 EPS change or 41.76 % from last quarter’s $0.91 EPS. TEVA’s profit would be $577.37M giving it 8.70 P/E if the $0.53 EPS is correct. After having $0.64 EPS previously, Teva Pharmaceutical Industries Limited’s analysts see -17.19 % EPS growth. The stock increased 1.54% or $0.28 during the last trading session, reaching $18.45. About 8.58 million shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has risen 22.93% since January 12, 2018 and is uptrending. It has outperformed by 22.93% the S&P500.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Coverage

Among 9 analysts covering Teva Pharmaceutical Indus (NYSE:TEVA), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Teva Pharmaceutical Indus had 12 analyst reports since July 16, 2018 according to SRatingsIntel. The rating was upgraded by BTIG Research to “Neutral” on Monday, September 17. As per Friday, September 7, the company rating was downgraded by Credit Suisse. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Neutral” rating given on Monday, July 16 by Cantor Fitzgerald. The stock has “Underperform” rating by Bank of America on Friday, November 2. The company was maintained on Monday, August 6 by Barclays Capital. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Buy” rating given on Thursday, January 3 by Bank of America. As per Monday, October 1, the company rating was maintained by Goldman Sachs. Leerink Swann upgraded the stock to “Market Perform” rating in Monday, October 1 report. The firm earned “Neutral” rating on Monday, September 17 by Credit Suisse. Mizuho maintained the shares of TEVA in report on Monday, September 17 with “Buy” rating.

Teva Pharmaceutical Industries Limited develops, makes, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company has market cap of $20.10 billion. It operates through two divisions, Generic Medicines and Specialty Medicines. It currently has negative earnings. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

More notable recent Teva Pharmaceutical Industries Limited (NYSE:TEVA) news were published by: Seekingalpha.com which released: “4 Reasons To Buy Teva – Seeking Alpha” on November 01, 2018, also Seekingalpha.com with their article: “FDA to “take action” against branded drug makers using scare tactics to thwart biosimilar competition – Seeking Alpha” published on January 10, 2019, Seekingalpha.com published: “Teva down 3% premarket on expanded investigation into generic drug price fixing – Seeking Alpha” on December 10, 2018. More interesting news about Teva Pharmaceutical Industries Limited (NYSE:TEVA) were released by: 247Wallst.com and their article: “Top Analyst Upgrades and Downgrades: AbbVie, Agilent, Albermarle, Apple, Boeing, Cheniere, First Solar, HCA, LabCorp, Lumber Liquidators, Teva and More – 24/7 Wall St.” published on January 03, 2019 as well as Seekingalpha.com‘s news article titled: “Teva: It Will Get Worse – Seeking Alpha” with publication date: May 14, 2018.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.